All In MedTech

Device Trial Radar · NCT03556891

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Pivotal Study of Subcutaneous Tibial Nerve Stimulation With eCoin for Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

133

Actual

Start

Sep 4, 2018

Primary completion

Apr 12, 2020

Study completion Sep 18, 2024

Sponsor

Lead sponsor
Valencia Technologies CorporationNot on our public-company list
Sponsor type
Industry
First posted
Jun 14, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.

Conditions

  • Overactive Bladder
  • Urge Incontinence
  • Incontinence, Urinary
  • Urinary Urge Incontinence

Interventions

  • eCoin Tibial Nerve StimulationDevice

    Subcutaneous stimulation of the tibial nerve using the eCoin device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.Time frame: 48 weeks after device activation.
  2. Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.Time frame: 52 weeks after implantation.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente

    Downey, California

  • Sequoia Urology Center

    Redwood City, California

  • Kaiser Permanente

    San Diego, California

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.